The First-in-Human, Single-Center, Randomized, Double-Blind, Placebo-Controlled Single- and Multiple- Ascending Dose Study to Evaluate the Safety and Tolerability of WS016 in Healthy Chinese Volunteers
Latest Information Update: 01 Mar 2024
At a glance
- Drugs WS 016 (Primary)
- Indications Hyperkalaemia
- Focus Adverse reactions; First in man
- Sponsors Waterstone Pharmaceuticals
Most Recent Events
- 01 Mar 2024 New trial record